Notable clinical activity of immune checkpoint inhibitors with or without brentuximab vedotin in relapsed or refractory gray zone lymphoma

Authors

Institutions

Publication Details

Journal
Haematologica
Published
2026-07-16
DOI
https://doi.org/10.3324/haematol.2026.301128
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Notable clinical activity of immune checkpoint inhibitors with or without brentuximab vedotin in relapsed or refractory gray zone lymphoma

Iván Dlouhy, Nina Abreu, Diana Viegas, Tiago Maia et al.
Haematologica
Cancer Immunotherapy and Biomarkers
article

Notable clinical activity of immune checkpoint inhibitors with or without brentuximab vedotin in relapsed or refractory gray zone lymphoma

Iván Dlouhy, Nina Abreu, Diana Viegas, Tiago Maia, MG Silva, José Cabeçadas
article en

Abstract

No abstract available for this paper.
Haematologica
Instituto Português de Oncologia de Coimbra Francisco Gentil (PT)
Eli Lilly and Company, AstraZeneca, Gilead Sciences, Ministério da Educação
Zero hunger
Openalex Percentile: Top 12%
Cancer Immunotherapy and Biomarkers
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.